PMOS (formerly PCOS) and Anovulatory Infertility: Evidence-Based Decisions from Ovulation Induction to IVF, Including OHSS Prevention

Anovulatory infertility in PMOS (formerly PCOS) is a sequence of decisions - IVF is not the first move, and when stimulation is used, preventing ovarian hyperstimulation syndrome is part of the plan.

It is about anovulatory infertility, not an ultrasound picture

This guide is for women seeking pregnancy who are not ovulating regularly due to PMOS (Polyendocrine Metabolic Ovarian Syndrome, formerly known as PCOS - polycystic ovary syndrome), not for those who simply have polycystic-appearing ovaries on a routine scan. Having multi-follicular ovaries on ultrasound is a common morphological finding and does not equal infertility on its own if cycles are ovulatory and conception occurs naturally.

Diagnostic criteria established in international consensus define polycystic ovary syndrome through the revised Rotterdam framework, requiring at least two of three features: irregular or absent ovulation, signs of clinical or biochemical androgen excess, and polycystic ovarian morphology on ultrasound or elevated anti-Müllerian hormone. When true anovulation is confirmed alongside these features, it creates anovulatory infertility because an egg is not being released predictably each month. Clarifying this distinction early prevents unnecessary distress and ensures that medical therapy targets real physiological obstacles rather than incidental imaging findings.

What comes before IVF?

Before considering assisted reproduction, most women with anovulatory PMOS should begin with oral ovulation induction, primarily using letrozole to help the ovary release an egg in a predictable time. Advanced interventions such as IVF are reserved for situations where simpler, less invasive approaches fail to restore ovulation or achieve pregnancy, or when additional reproductive barriers exist.

International recommendations identify letrozole as the first-line oral agent for ovulation induction in women with anovulatory infertility related to PMOS (Teede et al., 2023). While letrozole PMOS protocols represent international best practice, local prescription and licensing details should be verified with your physician in the clinic. Letrozole use for ovulation induction remains off-label in many countries, despite being supported by substantial evidence of efficacy and safety. By temporarily modulating estrogen feedback to the brain, letrozole encourages the pituitary gland to release its own follicle-stimulating hormone, prompting the growth and release of a single mature egg without negatively affecting the uterine lining.

When oral medications do not restore ovulation or lead to pregnancy, second-line options include low-dose gonadotropin injections under careful ultrasound monitoring. This stepped approach aims to achieve monofollicular ovulation while avoiding the recruitment of too many follicles at once. In selected clinical circumstances, laparoscopic ovarian drilling may be considered as an alternative second-line procedure, though it is used far less frequently today and remains an individualized surgical option rather than a universal standard.

When is IVF the right next step?

In vitro fertilization becomes the appropriate clinical pathway when structured ovulation induction has failed to produce a pregnancy despite verified ovulatory cycles, or when other biological factors prevent conception through simpler means. Moving to IVF is a strategic escalation designed to overcome specific physical hurdles, not an automatic default for every PMOS diagnosis.

Specialists evaluate several decisive indications when determining whether to advance to IVF:

• Completion of Ovulation Induction: Several well-monitored cycles of oral agents or cautious gonadotropin therapy that restored regular ovulation but did not result in a clinical pregnancy.
• Concurrent Fallopian Tube Occlusion: Documented bilateral tubal blockage or significant pelvic adhesive disease where an egg cannot naturally meet sperm.
• Co-Existing Male Factor Subfertility: Significant reductions in partner sperm count, motility, or morphology that require laboratory preparation, micro-insemination (ICSI), or advanced embryology.
• Time-to-Conception Pressures: Situations involving advancing maternal age where prolonged trials of timed intercourse could compromise reproductive potential due to age-related changes in egg genetics.

When these clinical indications are met, transitioning to IVF provides the embryology team with direct oversight of fertilization and embryo development, while allowing the clinical team to design a cycle centered on patient safety.

Why does OHSS prevention require particular attention in women with PMOS undergoing IVF?

Because ovaries with polycystic architecture hold a large pool of resting follicles, controlled stimulation carries an inherent vulnerability to ovarian hyperstimulation syndrome (OHSS), making OHSS prevention IVF strategies a non-negotiable medical responsibility. Modern reproductive medicine possesses the protocols and tools required to prevent severe hyperstimulation, and proactive risk reduction must be integrated into the treatment plan before stimulation begins.

International guidelines from ESHRE ovarian stimulation guideline (2025 update) and ASRM (2024) establish a clear clinical framework for predicted high responders:

• GnRH Antagonist Protocol: Gonadotropins are administered alongside an antagonist medication that prevents premature ovulation without over-suppressing the ovaries, providing a flexible framework that drastically lowers hyperstimulation risks compared to traditional long agonist protocols.
• Individualized Starting Dose: Gonadotropin dosing is carefully calibrated to baseline biomarkers and patient biology to achieve an adequate egg cohort while avoiding explosive multifollicular growth.
• GnRH Agonist Trigger: Instead of using human chorionic gonadotropin (hCG) to trigger final egg maturation, an agonist medication is utilized. This induces a natural surge of luteinizing hormone that matures the eggs while triggering rapid regression of the hormone-producing cells in the ovary, effectively neutralizing early-onset OHSS.
• Elective Cryopreservation (Freeze-All): All viable blastocysts are safely vitrified for transfer in a subsequent, non-stimulated cycle. This prevents exposure to the rising pregnancy hormones that cause late-onset OHSS, allowing the body to return to baseline physiology before an embryo is placed in the uterus.

When high egg numbers yield multiple good-quality blastocysts, it is equally important to safeguard the pregnancy itself. Transferring a single embryo rather than two remains the standard of care to prevent twin gestations and maternal-fetal complications, a biological principle detailed in our discussion on transferring two embryos versus one.

How to read a high AMH in PMOS?

A high anti-Müllerian hormone concentration reflects a large quantitative pool of growing antral follicles, but it does not measure the genetic competence or biological quality of individual eggs. AMH is an accurate metric of ovarian quantity and hyperstimulation vulnerability, not a guarantee of reproductive ease or embryo euploidy.

Understanding this biological distinction prevents both false reassurance and undue worry:

• Quantitative Follicle Yield: High AMH values correlate with the number of eggs likely to be retrieved during an IVF cycle, guiding your doctor to choose safer, lower starting doses of stimulation medications.
• Independence of Egg Quality: As explored in our clinical guide on evaluating low AMH in clinical practice, ovarian reserve markers measure volume, not intrinsic oocyte health. The primary biological determinant of egg developmental competence and chromosomal normality remains female age.
• Metabolic Influences: In polycystic ovary syndrome, elevated AMH often coexists with systemic insulin resistance and local ovarian inflammation, which can influence how follicles develop even when the numerical supply is high.

Evaluating AMH alongside maternal age, body mass index, and cycle regularity allows your clinician to anticipate how your ovaries will behave during treatment without making unwarranted assumptions about pregnancy outcomes.

What to assess before treatment in Dubai (biology, not a clinic brochure)

Before initiating treatment for PMOS IVF care in Dubai, the clinical focus must be placed on comprehensive biological evaluation rather than laboratory promises or commercial marketing. A safe and effective care plan begins with thorough diagnostic mapping to determine whether assisted reproduction is genuinely necessary or if simpler interventions remain open to you.

A thorough baseline assessment should encompass:

• True Ovulatory Status: Documenting whether spontaneous ovulation occurs using mid-luteal progesterone testing or cycle monitoring, distinguishing true anovulation from irregular but ovulatory cycles.
• Metabolic Health Without Weight Stigmatization: Evaluating fasting glucose, insulin dynamics, lipid profiles, and cardiovascular indicators. The goal is supporting cellular metabolism, improving reproductive receptivity, and ensuring a healthy pregnancy environment, without reducing patient care to simplistic judgments about body weight.
• Complete Semen Analysis: Verifying partner sperm parameters before initiating any female therapy, confirming that male factor subfertility is not an unaddressed contributor to the couple's delay in conceiving.
• Tubal Patency Testing: Assessing whether the fallopian tubes are open and functional through ultrasound-based contrast imaging or hysterosalpingography before prescribing oral ovulation medications.
• Proactive OHSS Risk Planning: A detailed medical discussion outlining antagonist protocols, agonist triggering, and planned cryopreservation before any gonadotropin injection is ordered, ensuring you understand how your safety is prioritized from day one.

Frequently Asked Questions

Does having PMOS (PCOS) mean I have to go straight to IVF?

No. Most women with anovulatory polycystic ovary syndrome do not require IVF as their first treatment. Evidence-based guidelines recommend beginning with oral ovulation induction medications like letrozole, which successfully restore ovulation and lead to pregnancy in a substantial proportion of patients. IVF is considered an advanced step, utilized only when oral therapies fail to yield a pregnancy or when additional issues, such as blocked fallopian tubes or significant male subfertility, are present.

Is letrozole safe for ovulation induction?

Yes. Extensive international research and clinical guidelines recognize letrozole as a safe and effective first-line medication for inducing ovulation in women with PMOS / PCOS. Large-scale cohort studies demonstrate that when taken for a short period in the early follicular phase, congenital malformation rates are comparable to those seen with clomiphene citrate and natural conception. While international bodies recommend letrozole as the preferred oral agent, local licensing considerations should be reviewed with your physician in the clinic.

Does a freeze-all strategy reduce my chances of having a baby?

No. Clinical evidence demonstrates that elective blastocyst cryopreservation yields cumulative live birth rates equivalent to, and in women with high ovarian response often higher than, fresh embryo transfers. Pausing transfer allows your hormone levels and uterine lining to return to a completely natural, receptive state following stimulation, creating an optimal environment for implantation while protecting you from late-onset OHSS.

Does a high AMH level mean my eggs are healthy?

Not necessarily. A high AMH level indicates a generous reserve in terms of egg quantity and follicular recruitment potential, but it does not indicate egg quality. Chromosomal normality and developmental competence are primarily determined by maternal age rather than the quantity of remaining follicles. A high AMH requires careful medical management to prevent overstimulation, but embryo development depends on broader biological factors.

Can severe ovarian hyperstimulation syndrome (OHSS) be avoided?

In modern clinical practice, severe OHSS is largely preventable through proactive protocol selection. By utilizing a GnRH antagonist protocol, selecting conservative starting medication doses, substituting the conventional hCG trigger with a GnRH agonist, and vitrifying all embryos for subsequent transfer, the physiological chain of events that causes severe fluid shifts and vascular complications is neutralized.

References

1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023;38(9):1655-1679.
2. Teede HJ et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026;407:2329–2339.
3. ESHRE Guideline Group on Ovarian Stimulation. ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025. Hum Reprod. 2026.
4. Practice Committee of the American Society for Reproductive Medicine. Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2024;121(2):230-245.

Disclaimer: This article is for general educational purposes only and does not constitute medical advice, formal diagnosis, or a treatment recommendation. Healthcare choices and clinical pathways must be determined in direct consultation with a licensed reproductive endocrinologist following a comprehensive, individualized medical assessment.

About the author

Dr Ewa Goncikowska, MD, PhD

Specialist in Gynaecological Endocrinology, Reproduction & Infertility